Skip to main content
. 2020 Oct 23;14(1):100887. doi: 10.1016/j.tranon.2020.100887

Fig. 3.

Fig. 3

Effects of anti-EGF VacAbs in combination with ALK and RET TKIs in ALK and RET translocated cell lines, respectively. TKI's were added at the final concentrations indicated, antibodies at a 1/50 dilution and EGF at 10 ng/mL. Medium was RPMI+0.5% HS in all cases. (A-B) Growth curves of proliferation assays at 4 and 16 days, respectively. (C-D) Percentage of cells in S + G2/M phase by flow cytometry. (E-F) Percentage of apoptotic cells by annexin V analysis. Final concentrations of the selected TKIs were 100 nM brigatinib in H2228 (A, C, E) and 100 nM BLU-667 in LC-2/ad (B, D, F). Results shown are representative of three different experiments. Medium was RPMI+0.5% HS. Ab, anti-EGF VacAbs.